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Abstract
Introduction N-acetyltransferase 2 is a polymorphic enzyme in
humans. Women who possess homozygous polymorphic alleles
have a slower rate of metabolic activation of aryl aromatic
amines, one of the constituents of tobacco smoke that has been
identified as carcinogenic. We hypothesized that women with
breast cancer who were slow acetylators would be at increased
risk of breast cancer associated with active and passive
exposure to tobacco smoke.
Methods We used a case-only study design to evaluate
departure from multiplicativity between acetylation status and
smoking status. We extracted DNA from buccal cell samples
collected from 502 women with incident primary breast cancer
and assigned acetylation status by genotyping ten single-
nucleotide polymorphisms. Information on tobacco use and
breast cancer risk factors was obtained by structured
interviews.
Results We observed no substantial departure from
multiplicativity between acetylation status and history of ever
having been an active smoking (adjusted odds ratio estimate of
departure from multiplicativity = 0.9, 95% confidence interval
0.5 to 1.7) or ever having had passive residential exposure to
tobacco smoke (adjusted odds ratio = 0.7, 95% confidence
interval 0.4 to 1.5). The estimates for departure from
multiplicativity between acetylation status and various measures
of intensity, duration, and timing of active and passive tobacco
exposure lacked consistency and were generally not supportive
of the idea of a gene–environment interaction.
Conclusion In this, the largest case-only study to evaluate the
interaction between acetylation status and active or passive
exposure to tobacco smoke, we found little evidence to support
the idea of a departure from multiplicativity.
Introduction
The aromatic and heterocyclic amines are among the constit-
uents of tobacco smoke that have been identified as carcino-
gens [1,2]. These carcinogens require host-mediated
metabolic activation to electrophiles, which readily bind nucle-
ophilic DNA, to induce a mutation and, ultimately, cancer [3].
Two pathways metabolize aromatic amines [4]. First, aromatic
amines can be N-acetylated in the liver by N-acetyltransferase-
2 (NAT2) or N-acetyltransferase-1 (NAT1) [5]. This is a detoxi-
fying pathway. Second, aromatic amines and heterocyclic
amines can be N-oxidized by P450 enzymes in the liver or in
extrahepatic tissues [4]. This oxidation competes with the
hepatic N-acetylation for aromatic amines but not for heterocy-
clic amines. The product of the oxidation is then either O-
acetylated by NAT2 or NAT1, a reaction that yields the acti-
vated electrophile, or detoxified by competing enzymatic path-
ways [4,6]. The NAT2 enzyme therefore has a dual role: it
detoxifies aromatic amines hepatically but may also play a role
in activation of aromatic amines and heterocyclic amines in ext-
rahepatic tissues such as the breast.
NAT2 is a polymorphic enzyme in humans [5,7-10]. Those
who possess homozygous wild-type alleles are classified as
fast acetylators – because they have a higher rate of metabolic
AOR = adjusted odds ratio estimate of departure from multiplicativity; BMI = body mass index; CI = confidence interval; NAT = N-acetyltransferase; 
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activation of aryl aromatic amines – and those who possess
certain polymorphisms are called slow acetylators because
they have a lower rate of metabolic activation of these amines
[9,11]. Depending on which metabolic pathway predominates
at critical junctures of exposure and tissue susceptibility, fast
acetylators may be at higher or lower risk of smoking-induced
breast carcinogenesis than slow acetylators. Postmenopausal
women who smoke and have a reduced ability to detoxify by-
products of tobacco smoke, as measured by their NAT2 gen-
otype (slow acetylators), have an excess risk of breast cancer
[12-14]. In one of these studies, this excess risk was found to
be limited to women who had smoked for 20 years or more
[14]. In another study, the postmenopausal women who were
rapid acetylators were found to be at highest risk [15]. In a fifth
study, the association between smoking and breast cancer
showed little dependence on acetylation rate [16].
Most epidemiologic studies that have examined the relation
between active cigarette smoking and breast cancer have
found weak or null associations [17,18]. A meta-analysis of the
studies that excluded from the analysis those women who had
been passively exposed reported that the risk of breast cancer
for active smokers was more than twice as much as that for
women never actively or passively exposed to tobacco smoke
[19]. Studies comparing women who were passive smokers
with women who had never been either active or passive
smokers have also shown consistent elevations in breast can-
cer risk associated with smoking [20-23]. Recently, two case–
control studies [24,25] have reported effect modification by
acetylation status for both active and passive smokers. Both
studies found stronger associations between breast cancer
risk and passive exposure to smoke among rapid acetylators.
Though both studies also found an association between active
smoking and breast cancer risk, the magnitude of the risk was
greater among slow acetylators in the study by Chang-Claude
and colleagues [24] and among fast acetylators in the study by
Morabia and colleagues [25]. Inconsistent findings have pre-
vented any meaningful conclusions from being drawn about
the interaction of acetylation status and exposure to tobacco
smoke in the etiology of breast cancer.
We collected genetic and behavioral information from incident
primary breast cancer cases arising in five different sites
across the United States. We used a case-only design to
examine the potential interaction between acetylation status –
as assigned by NAT2 genotype – and self-reported active or
passive smoking status. We hypothesized that slow acetyla-
tors would be at increased risk of breast cancer associated
with both active and passive smoking, and that these risks
would be more pronounced among women whose exposure
began before their first pregnancy or at an early age. The case-
only design is optimal for assessing multiplicative interaction
when the genotype and environmental exposure are independ-
ent of one another. This investigation is the largest case-only
study to examine the interaction between NAT2 acetylation
status and history of tobacco exposure as it relates to the risk
of breast cancer.
Materials and methods
Study population
The cases of female breast cancer included in this analysis
were identified as parts of two study populations [26,27]. The
first population included women with pathologically confirmed
incident invasive breast cancer diagnosed between 1987 and
1993 among residents of eight towns on Cape Cod, Massa-
chusetts, and that were reported to the Massachusetts Can-
cer Registry. The second population included women with
pathologically confirmed, incident stage I, stage II, or stage IIIa
breast cancer that were diagnosed from December 1996 to
September 1999 at hospitals in Los Angeles, California;
Rhode Island; Minnesota; and North Carolina.
Data collection
Buccal cell samples for genotyping
Introductory letters were mailed to breast cancer patients in
2001 and 2002. A trained interviewer followed the letter with
a telephone call to answer questions and solicit participation.
Patients who agreed to participate were sent an enrollment
package containing an introductory letter, summary informa-
tion about the study, an informed consent form, instructions for
submitting a mouthwash sample, a safety-sealed sample of
mouthwash, and a wide-mouth sample-collection bottle. Par-
ticipants collected the sample and returned it in a postage-
paid box along with their informed consent form. Buccal cells
were precipitated by centrifugation and stored at -70°C until a
batch of 90 samples had been collected. Batches were sent
by overnight delivery on dry ice to Qiagen Genomics (Bothell,
WA, USA) for DNA extraction and genotyping.
Qiagen Genomics applied proprietary Masscode technology
to measure Masscode tags, which are low-molecular-weight
compounds linked to the DNA via a photocleavable linker. The
tag is cleaved in flow into a mass spectrometer, and a Micro-
soft Access database converts the raw analytical data into sta-
tistically generated genotype calls. The assay has been
validated in over one million genotypes. Existing primers were
used to characterize NAT2 genotypes at ten single-nucleotide
polymorphisms (SNPs) in each buccal cell sample.
The Qiagen genotyping data characterized each participant as
homozygous wild-type, heterozygous, or homozygous poly-
morphic at each SNP. Inferred haplotypes were estimated
from the genotyping data using an expectation-maximization
algorithm implemented in the software program SNPHAP
http://www-gene.cimr.cam.ac.uk/clayton/software/, and the
predicted haplotypes with the highest probability were used
for the primary analyses.Available online http://breast-cancer-research.com/content/7/3/R385
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Interview data
Patients who were included in the study were interviewed on
the telephone by trained interviewers using a structured inter-
view to obtain information on demographic characteristics,
history of active and passive exposure to tobacco smoke, and
known or suspected risk factors for breast cancer. Patients
from the Cape Cod study population were interviewed
between March 1997 and March 1998. Patients from the sec-
ond study population were interviewed approximately 40
months after their date of diagnosis to gather the variables pri-
marily used in this analysis.
Analytic variables
NAT2 genotype
The literature on the expression of specific SNPs in the NAT2
gene guided the phenotypic assignments for each haplotype
used in this study [11,28-34]. We considered a woman a
'rapid acetylator' if she was homozygous for the NAT2*4a or
NAT2*12 haplotype, an 'intermediate acetylator' if she was
heterozygous for the NAT2*4a or NAT2*12 haplotype, and a
'slow acetylator' if she had any other combination of the NAT2
polymorphisms listed in Table 1.
Tobacco exposure
We considered a woman an active smoker if she reported
smoking 100 or more cigarettes in her lifetime, and a passive
smoker if she was not herself a smoker but reported living with
someone who was a smoker. Women who were neither active
nor passive smokers were considered separately. For women
who reported having smoked 100 or more cigarettes in their
lifetime or who lived with someone who smoked, information
on the duration, intensity, and timing of exposure to tobacco
smoke (active or passive) was also collected.
Covariates
In addition to information about smoking, we collected infor-
mation on health and behavioral risk factors, including alcohol
use, body mass index (BMI), family history of breast cancer
(yes or no), history of benign breast disease, and parity. BMI
was calculated as weight divided by the square of height (kg/
m2). A woman was considered to have a first-degree family his-
tory of breast cancer if she reported that her mother, sister(s),
or daughter(s) had been diagnosed with breast cancer. We
defined alcohol use according to the number of drinks a
woman reported 'usually' having: nondrinker, ≤  one drink/
month, few drinks/month, few drinks/week, almost every day,
and unknown.
Analytic strategy
Ambrosone and colleagues [12] found that the rapid and inter-
mediate arylamine N-acetyltranferase activity groups do not
differ in their phenotypic expression (acetylation status).
Based on this finding and others [35,36], we collapsed rapid
and intermediate acetylators into the group of rapid acetyla-
tors. We examined the interaction of acetylation status and
exposure to tobacco smoke among the breast cancer cases
available for analysis. We used logistic regression analysis in
SAS [37] to quantify departure from multiplicativity. We gen-
erated odds ratios (ORs) and 95% confidence intervals (CIs)
to estimate the departure from multiplicativity between smok-
ing status and acetylation status (gene–environment interac-
tion). We examined the ORs separately for active and passive
smokers. Women who were fast acetylators and who had
never been either active or passive smokers were the refer-
ence group for all analyses. We controlled for the influence of
potential breast cancer risk factors including age at diagnosis
of breast cancer, alcohol consumption, BMI, first-degree family
Table 1
Distribution of NAT2 haplotypes and their gene product acetylator phenotype in 502 breast cancer patients
Acetylator phenotype Haplotype References
Status No. %
Fast 24 4.8 NAT2*4/NAT2*4 31–34
Intermediate 158 31.5 All intermediate 14
148 93.7 NAT2*4/- 35
10 6.3 NAT2*12a/-
Slow 320 63.7 All slow 14,33,36
81 24.6 NAT2*5b/NAT2*5b
139 43.4 NAT2*5b/NAT2*6a
37 11.2 NAT2*5b/- 14,31–33,36
43 13.1 NAT2*6a/NAT2*6a
18 6.1 NAT2*6a/- 14,36,37
2 3.3 NAT2*5c/-
-, any other haplotype yielding heterozygosity; NAT, N-acetyltransferase.Breast Cancer Research    Vol 7 No 3    Lash et al.
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Table 2
Distribution of breast cancer risk factors according to arylamine N-acetyltransferase activity (acetylation status)
NAT2
Fast Slow
Characteristic No. (%) No. (%) OR 95% CI
Age (years)
<50a 22 (12) 38 (12) 1.0 -
50 to 59 15 (8) 28 (9) 1.1 0.5 to 2.4
60 to 69 59 (32) 103 (32) 1.0 0.5 to 1.9
70+ 86 (47) 151 (47) 1.0 0.6 to 1.8
Alcohol use
Nondrinkera 45 (14) 32 (18) 1.0 -
≤  1 drink/month 75 (23) 43 (24) 1.2 0.7 to 2.2
Few drinks/month 77 (24) 39 (21) 1.4 0.8 to 2.5
Few drinks/week 76 (24) 39 (21) 1.4 0.8 to 2.5
Almost every day 40 (12) 24 (13) 1.2 0.6 to 2.3
Unknown 7 (2) 5 (3) 1.0 0.3 to 3.4
Body mass index (BMI) (kg/m2)
<20.0a 30 (17) 59 (19) 1.0 -
20.0 to 24.9 114 (65) 196 (62) 0.9 0.5 to 1.4
25.0 to 29.9 24 (14) 50 (16) 1.1 0.5 to 2.0
30.0+ 8 (4) 11 (3) 0.7 0.3 to 1.9
First-degree family history of breast cancerb
Noa 140 (78) 240 (77) 1.0 -
Yes 39 (22) 72 (23) 1.1 0.7 to 1.7
Parity
Nulliparousa 72 (23) 27 (15) 1.0 -
1 live birth 22 (7) 22 (12) 0.4 0.2 to 0.8
2 live births 56 (17) 43 (24) 0.5 0.3 to 0.9
3 live births 70 (22) 48 (25) 0.5 0.3 to 1.0
4 live births 46 (14) 21 (12) 0.8 0.4 to 1.6
5 or more live births 54 (17) 21 (12) 1.0 0.5 to 1.9
Geographical location
Cape Cod, Massachusettsa 91 (50) 178 (56) 1.0 -
Los Angeles, California 27 (15) 33 (10) 0.6 0.3 to 1.1
Rhode Island 17 (9) 38 (12) 1.1 0.6 to 2.1
Minnesota 28 (15) 34 (11) 0.6 0.3 to 1.1
North Carolina 19 (10) 37 (12) 1.0 0.5 to 1.8
History of benign breast disease
Noa 116 (65) 206 (65) 1.0 -
Yes 63 (35) 110 (35) 1.0 0.7 to 1.4
aReference level. bIncludes a woman's mother, sister(s), and/or daughter(s). -, not calculated; CI, confidence interval; NAT, N-acetyltransferase; 
OR, odds ratio.Available online http://breast-cancer-research.com/content/7/3/R385
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history of breast cancer, geographic location (state where
breast cancer diagnosis was made), and history of benign
breast disease using multiple variable logistic regression.
We also evaluated departure from multiplicativity for variables
describing the duration, intensity, and timing of active smoking
or exposure to passive smoking. For active smokers, we exam-
ined the ORs in categories of the number of packs of ciga-
rettes smoked per day, duration of smoking, age at onset of
smoking, when a woman began smoking in relation to the first
live birth of a child, and time since cessation of smoking. For
passive smokers, we examined the duration of passive expo-
sure, age when first passive exposure began, and when this
first passive exposure occurred in relation to the first live birth
of a child.
Results
Among the Cape Cod population, 330 of 483 eligible women
agreed to receive a sample collection kit; the remainder
refused or could not be contacted. Of the 330 who received a
kit, 272 returned a sample and 269 samples yielded DNA that
could be genotyped. Among the second study population
(from California, Rhode Island, Minnesota, and North Caro-
lina), 372 of 410 eligible women agreed to receive a sample
collection kit and the remainder refused or were unable to be
contacted. Of the 372 who received a kit, 321 returned a sam-
ple and 233 had samples that yielded DNA that could be gen-
otyped and had the requisite interview data. In both studies,
56% of eligible participants were genotyped and included in
the analysis. The proportion of smokers among nonpartici-
pants was not significantly different from that among partici-
pants in either study population. The mean age was greater
among nonparticipants than among participants (mean ages
66 years versus 61, respectively, in the Cape Cod population,
P = 0.0001; and 74 versus 73 in the second study population,
P = 0.03), reflecting greater losses to follow-up among older
women. Age was not associated with genotype among the
participants. The proportion of participants who were slow
acetylators, active smokers, and passive smokers did not vary
significantly with their site of enrollment. Among the geno-
typed controls in the Cape Cod study, the OR for association
of acetylation status (fast versus slow) with exposure to
tobacco smoke (women who had ever smoked actively versus
all the others studied) was 1.06 (P = 0.90). This finding is con-
sistent with those of earlier studies [12,14-17,24,25], in which
acetylation status and active smoking were not significantly
associated among controls.
Table 2 provides demographic and risk factor characteristics
for the 502 breast cancer patients in the analytic sample
according to acetylation status. The distribution of age, family
history of breast cancer, and history of benign breast disease
was nearly identical for fast and slow acetylators. There were
small differences in alcohol consumption and BMI between
fast and slow acetylators and a noticeable difference in the
proportion of women who had had one to three live births
(46% versus 61%, respectively). The great majority of the par-
ticipants (97%) were white (data not shown).
We observed no substantial departure from multiplicativity
between acetylation status and history of ever having smoked
actively (adjusted OR estimate of departure from multiplicativ-
ity (AOR) = 0.9) or of ever having experienced passive resi-
dential exposure to tobacco smoke (AOR = 0.7) (Table 3,
which also shows confidence intervals). The ratios of the
upper limits of the intervals to their lower limits were about 3
and 3.7 for the crude and adjusted estimates of effect, respec-
tively (Table 3). These ratios measure the precision of the esti-
mates of effect and indicate adequate precision about these
estimates.
Estimates for the departure from multiplicativity between
acetylation status and the various measures of intensity, dura-
tion, and timing of active and passive tobacco exposure are
presented in Table 4. For active smokers, we found estimates
lacking consistent directionality. The AOR estimates for
women in the categories with the highest intensity (packs/day)
and greatest length (in years) of smoking were in opposite
directions. For example, the departure from multiplicativity was
above the null for women who had smoked two or more packs
per day (AOR = 1.8) but below the null for women who had
smoked for 40 or more years (AOR = 0.7). For the variables
describing the age at which a woman began smoking, when
she began smoking in relation to her first live birth, and the time
elapsed since she quit smoking, we observed estimates of
departure from multiplicativity both above and below the null.
The estimates for departure from multiplicativity between
acetylation status and the measures of duration and timing of
passive exposure to tobacco also lacked consistency. For the
variable describing the duration of passive exposure to
tobacco in the residence, we observed null and less than null
associations with slow acetylation status: AOR = 1.0 for <20
years, 0.6 for 20 to <40 years, and 0.8 for 40+ years. We
observed a departure from multiplicativity between slow
acetylation status and passive exposure occurring exclusively
before a woman's first live birth (AOR = 1.9), and a positive
departure for women whose first passive exposure to tobacco
smoke occurred between the ages of 12 and 20 (AOR = 2.4).
Discussion
In this, the largest case-only study to evaluate the interaction
between acetylation status and exposure to tobacco smoke,
we found little evidence to support a departure from multiplic-
ativity between acetylation status and a history of active smok-
ing for women with breast cancer. There is some suggestion
that women who were slow acetylators were at higher risk
from passive exposure to tobacco smoke before their first live
birth than women who had never been either passive or active
smokers. A similar positive departure was observed for womenBreast Cancer Research    Vol 7 No 3    Lash et al.
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who were first passively exposed between the ages of 12 and
20. The effect estimates observed in this study for measures
of intensity, duration, and timing of exposure showed no con-
sistent pattern and in some instances were statistically
unstable.
Our study is one of only a few to assess the interaction
between exposure to tobacco smoke and acetylation status in
relation to breast cancer risk. Hunter and colleagues [16], in
addition to examining the association between slow acetyla-
tion status and the risk of breast cancer, for which they
reported a null association, found no evidence of an interaction
between recent smoking status and NAT2 acetylation status
among 706 postmenopausal women (cases and controls).
Recently, two studies that removed passive smokers from the
analysis of the unexposed group found suggestions of an inter-
action between tobacco exposure and acetylation status. Both
reported a greater breast cancer risk among passive smokers
who were fast acetylators [24,25]. The findings among active
smokers were not consistent, however. Morabia and col-
leagues [25] found that active smokers who were fast acetyla-
tors were at greater risk, whereas Chang-Claude and
colleagues [24] found the greater risk from active smoking
among slow acetylators. By parsing their cases into
contingency tables (genotype by smoking group) and applying
a case-only analysis, we obtained estimates of departure from
multiplicativity for both studies very similar to ours, but with
wider CIs.
In the only other case-only analysis, Ambrosone and col-
leagues [12] found a strong positive departure from multiplic-
ativity between acetylation status and smoking at an early age
(<18) and for smoking 20 or more cigarettes 20 years previ-
ously. Overall, we found departures from multiplicativity
between acetylation status in relation to both active and pas-
sive exposure to tobacco smoke below the null. In suba-
nalyses, we did find a positive departure from multiplicativity
between acetylation status and smoking initiation between 14
and 15 years of age, and, separately, for first passive exposure
to tobacco smoke between the ages of 12 and 20. Both find-
ings are consistent with the hypothesis that environmental
insults to developing breast tissue may increase the tissue's
susceptibility to carcinogenesis, and thus may increase a
woman's risk of breast cancer [38,39]. However, the lack of a
consistent directionality to our estimates for the other age-at-
initiation categories (≤  13 and 16 to 17 years) suggests that
these may be chance findings.
To date, numerous polymorphisms on the NAT2 gene have
been identified (Table 1), which has furthered our understand-
ing of NAT2 phenotypes and improved our ability to assign
acetylation status to the breast cancer cases in this study. The
genotyping procedures employed in this analysis are more
accurate than the PCR-RFLP (PCR–restriction fragment
length polymorphism) techniques used in previous studies
[12,16,25]. Consequently, the rates of misclassification of
acetylation status in this study should be less than in those
studies.
Misclassification of either the genetic or environmental varia-
bles involved in an assessment of interaction by case–control
design can give rise to the appearance of interaction when, in
fact, there is none [40]. Our analysis of interaction using case-
only data provides greater control over the impact of potential
misclassification errors, because there are only two variables
that are susceptible to misclassification – acetylation status
and smoking status. If the misclassification rates are nondiffer-
ential, as one would expect, then the estimates of departure
from multiplicativity will be biased towards the null [41]. As dis-
cussed above, in the previous case–control analyses, the
impact of misclassification is less predictable. It is therefore
possible that findings from previous studies evaluating the
interaction of acetylation status and exposure to tobacco
smoke in relation to breast cancer risk may have generated
spurious estimates of interaction, even if the misclassification
was nondifferential. As discussed above, case-only estimates
derived from these studies were similar to ours. The attenua-
tion of the interaction after reanalysis using the case-only
design further suggests that the published case–control
results may have been more susceptible to misclassification.
By genotyping more SNPs with a more accurate method and
by implementing a case-only design, our analysis provides a
more valid assessment of the multiplicative interaction
Table 3
Departure from multiplicativity between acetylation status and smoking status among patients with breast cancer
Acetylation status Crude statistic Adjusted statistica
Smoking status Slow Fast OR 95% CI OR 95% CI
Active smoker 162 85 1.04 0.59 to 1.82 0.88 0.45 to 1.70
Passive smoker 114 73 0.85 0.48 to 1.52 0.75 0.39 to 1.45
Nonsmoker 44 24 1.0 - 1.0 -
aControlling for age, alcohol consumption, body mass index, family history of breast cancer, family history of benign breast disease, parity, and 
geographical location. -, not calculated; CI, confidence interval; OR, odds ratio.Available online http://breast-cancer-research.com/content/7/3/R385
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Table 4
Departure from multiplicativity between acetylation status and smoking status among patients with breast cancer
Acetylation status
Smoking Slow Fast OR Adjusted ORa Adjusted 95%CI
Nonsmokers 44 24 1.0 1.0 -
Active smokers
Packs (per day)
<1 96 47 1.11 0.97 0.48 to 1.95
1 to <2 53 33 0.88 0.74 0.35 to 1.60
≥  2 12 2 3.27 1.80 0.33 to 9.81
Data missing 1 3
Duration (years)
<20 39 29 0.73 0.59 0.26 to 1.35
20 to <40 79 25 1.72 1.32 0.62 to 2.81
40+ 43 30 0.78 0.74 0.33 to 1.63
Data missing 1 1
Duration (years) in relation to first birth
Nulliparous 41 11 2.03 1.05 0.32 to 3.41
All before first 11 8 0.75 0.60 0.17 to 2.10
Before and after first 90 48 1.02 1.03 0.48 to 2.20
All after first 19 17 0.61 0.52 0.19 to 1.37
Data missing 1 1
Age started (years)
≤  13 4 3 0.73 0.63 0.11 to 3.48
14 to 15 22 7 1.71 1.94 0.61 to 6.19
16 to 17 35 18 1.06 0.79 0.32 to 1.94
18 to 21 67 35 1.04 0.94 0.45 to 1.99
22 to 29 19 11 0.94 0.84 0.31 to 2.30
≥  30 14 10 0.76 0.60 0.21 to 1.71
Data missing 1 1
Quit before diagnosis date (years)
Current or <5 32 12 1.45 1.25 0.50 to 3.19
5 to 15 37 19 1.06 0.82 0.35 to 1.95
>15 71 42 0.92 0.86 0.41 to 1.80
Data missing 22 12
Passive smokers
Duration (years)b
<20 34 18 1.03 0.99 0.43 to 2.33
20 to <40 48 36 0.73 0.61 0.29 to 1.28
40+ 29 18 0.88 0.81 0.33 to 2.01
Data missing 3 1
Duration (years) in relation to first birth
Nulliparous 20 14 0.78 0.52 0.16 to 1.69
All before first 20 8 1.36 1.85 0.59 to 5.83Breast Cancer Research    Vol 7 No 3    Lash et al.
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between NAT2 genotype and exposure to tobacco smoke in
relation to breast cancer.
Weighing against this advantage of the case-only design is the
limitation that only departure from multiplicativity can be
assessed. Many epidemiologists weigh departure from addi-
tive interaction more heavily, arguing that the additive scale
corresponds better to the biologic meaning of synergistic
effects [42]. A further limitation of the case-only design is its
reliance on the assumption that the genetic polymorphisms
and environmental exposure are independent of one another
[43]. Violations of this assumption can substantially distort the
estimates of interaction. However, NAT2 polymorphisms and
smoking history were not associated among the genotyped
controls in the Cape Cod study or among the controls in ear-
lier studies [12,14-17,24,25]. The absence of association
supports the assumption of independence required to validly
estimate departure from multiplicativity with the case-only
design.
These results must be interpreted with the following additional
limitations in mind. First, only 56% of eligible cases were avail-
able for analysis. Participation was not related to smoking sta-
tus and although participation was related to age, age was not
related to genotype. We expect that the selection of partici-
pants introduced no substantial bias, although we acknowl-
edge that our study of breast cancer survivors may have
influenced the estimates of effect in ways that we are unable
to anticipate. Second, haplotypes were inferred from genotyp-
ing data by assigning the haplotype with the maximum proba-
bility to each case. Forty-one percent of haplotype
assignments had probabilities of 100% and 91% had proba-
bilities of 80% or better. Less than 5% had probabilities of less
than 50%. We expect that the procedure used to infer haplo-
types introduced little error.
Conclusion
This large case-only analysis is the first to be able to assign
acetylation status on the basis of ten SNPs. No previous anal-
ysis assigned acetylation status on the basis of more than four.
In addition, the study involved the largest number of breast
cancer cases used to investigate the interaction between
NAT2 acetylation status and exposure to tobacco smoke as
related to breast cancer risk. The combination of the most
complete genotyping data and the large case-only design pro-
vides important advantages, the results of which do not sug-
gest any substantial interaction between acetylation status
and exposure to tobacco smoke in the etiology of breast can-
cer. Weighing against the null result is the potential for an
unanticipated bias towards the null to have arisen by selection
of breast cancer survivors from among the incident cases.
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